Södertälje, Sweden
Annoca has developed, validated and deployed a proprietary technology platform based on libraries of highly engineered human cells that enables high-precision and standardized analysis of T-cell biology. Our technology platform rapidly identifies and validates new disease antigens, in addition to identification, characterization and engineering of TCRs in an industrialised process. Anocca’s own manufacturing facility enables integration of technology-driven analyses into manufacturing control and multiple independent TCR-modified T-cell therapy (TCR-T) clinical programs.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Anocca AB on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
